Evidence map›Paper›PMID 31976585›Full record

ArticleEuropean journal of pain (London, England)2020

Blockade of BDNF signalling attenuates chronic visceral hypersensitivity in an IBS-like rat model.

Fei Fan, Ying Tang, Hengfen Dai, Yang Cao, Pei Sun, Yu Chen, Aiqin Chen, Chun Lin

Open access · hybridAbstract read
In one paragraph

Article in European journal of pain (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Fei FanSchool of basic Medical Sciences, Laboratory of Pain Research, Fujian Medical University, Fuzhou, China.ORCID 0000-0002-1166-0325
Ying TangSchool of basic Medical Sciences, Laboratory of Pain Research, Fujian Medical University, Fuzhou, China.
Hengfen DaiSchool of basic Medical Sciences, Laboratory of Pain Research, Fujian Medical University, Fuzhou, China.
Yang CaoSchool of basic Medical Sciences, Laboratory of Pain Research, Fujian Medical University, Fuzhou, China.
Pei SunSchool of basic Medical Sciences, Laboratory of Pain Research, Fujian Medical University, Fuzhou, China.
Yu ChenSchool of basic Medical Sciences, Laboratory of Pain Research, Fujian Medical University, Fuzhou, China.
Aiqin ChenSchool of basic Medical Sciences, Laboratory of Pain Research, Fujian Medical University, Fuzhou, China.
Chun LinSchool of basic Medical Sciences, Laboratory of Pain Research, Fujian Medical University, Fuzhou, China.
Fujian Medical University · CN

Funding

National Natural Science Foundation of China 81471138Natural Science Foundation of Fujian Province 2016Y9036Natural Science Foundation of Fujian Province 2018J01834Natural Science Foundation of Fujian Province 2018Y9069
6 · The paper itself

Abstract

backgroundIrritable bowel syndrome (IBS) is a common functional disease characterized by chronic abdominal pain and changes in bowel movements. Effective therapy for visceral hypersensitivity in IBS patients remains challenging. This study investigated the roles of brain-derived neurotrophic factor (BDNF) and tyrosine kinase receptor B (TrkB) and the effect of ANA-12 (a selective antagonist of TrkB) on chronic visceral hypersensitivity in an IBS-like rat model.

methodsAn IBS-like rat model was established through neonatal maternal separation (NMS), and visceral hypersensitivity was assessed by electromyographic (EMG) responses of the abdominal external oblique muscles to colorectal distention (CRD). Different doses of ANA-12 were injected intrathecally to investigate the effect of that drug on visceral hypersensitivity, and the open field test was performed to determine whether ANA-12 had side effects on movement. Thoracolumbar spinal BDNF, TrkB receptor and Protein kinase Mζ (PKMζ) expression were measured to investigate their roles in chronic visceral hypersensitivity. Whole-cell recordings were made from thoracolumbar superficial dorsal horn (SDH) neurons of lamina II.

resultsThe expression of BDNF and TrkB was enhanced in the thoracolumbar spinal cord of the NMS animals. ANA-12 attenuated visceral hypersensitivity without side effects on motricity in NMS rats. PKMζ expression significantly decreased after the administration of ANA-12. The frequency of spontaneous excitatory postsynaptic currents (sEPSCs) increased in the thoracolumbar SDH neurons of lamina II in NMS rats. The amplitude and frequency of sEPSCs were reduced after perfusion with ANA-12 in NMS rats.

conclusionsNeonatal maternal separation caused visceral hypersensitivity and increased synaptic activity by activating BDNF-TrkB-PKMζ signalling in the thoracolumbar spinal cord of adult rats. PKMζ was able to potentiate AMPA receptor (AMPAR)-mediated sEPSCs in NMS rats. ANA-12 attenuated visceral hypersensitivity and synaptic activity by blocking BDNF/TrkB signalling in NMS rats. SIGNIFICANCE: ANA-12 attenuates visceral hypersensitivity via BDNF-TrkB-PKMζ signalling and reduces synaptic activity through AMPARs in NMS rats. This knowledge suggests that ANA-12 could represent an interesting novel therapeutic medicine for chronic visceral hypersensitivity.

Indexed as

Irritable Bowel SyndromeVisceral PainAnimalsAnimals, NewbornBrain-Derived Neurotrophic FactorHumansMaternal DeprivationRatsSignal TransductionBrain-Derived Neurotrophic Factor

Identifiers

PMID31976585
PMCPMC7154558
OpenAlexW3001992982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.